Home > In process > Fear of progression in Parkinson's disease: Role of age and occupational status. > print

001     285034
005     20260206170625.0
024 7 _ |a 10.1177/1877718X251365243
|2 doi
024 7 _ |a pmid:41252262
|2 pmid
024 7 _ |a 1877-7171
|2 ISSN
024 7 _ |a 1877-718X
|2 ISSN
037 _ _ |a DZNE-2026-00159
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a D'Souza, Simone
|0 0000-0003-2133-714X
|b 0
245 _ _ |a Fear of progression in Parkinson's disease: Role of age and occupational status.
260 _ _ |a Amsterdam
|c 2026
|b IOS Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1770393847_716
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Background: Parkinson's disease (PD) is a slowly progressing neurodegenerative disorder, so it is likely that people with PD (PwPD) face increasing disability. PwPD thus experience various degrees of fear of progression (FoP), which can become dysfunctional. Objective: This study aims to examine the prevalence of and contributing factors to dysfunctional FoP in PwPD. Methods: The Fear of Progression Questionnaire-Short Form (FoP-Q-SF) was administered along with further questionnaires for non-motor symptoms; PD motor symptoms as reported by the Unified Parkinson's Disease Rating Scale Part III (UPDRS III) were obtained from patient charts. Results: 28% of the 105 PwPD (mean age 66 years, 56% Hoehn & Yahr stage I/II) were categorized as experiencing dysfunctional levels of FoP using the established cut-off score of ≥34. Our analyses revealed that the FoP-Q-SF underestimates the prevalence of dysfunctional FoP in older and non-working PwPD. Using a more appropriate cut-off, 33% of PwPD are classified as having dysfunctional levels of FoP. We found strong correlations of FoP with measures of anxiety, depression and quality of life. Disease duration was secondary to these factors. We found no associations between FoP and motor symptoms. Conclusions: Our findings confirm that dysfunctional FoP significantly impacts the psychological well-being of PwPD, affecting one in three PwPD and contributing to heightened anxiety, depression, and reduced quality of life. Future validation studies are needed to confirm the cut-off value proposed here and to enable a better integration of the concept of FoP into routine care for PwPD.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Parkinson's disease
|2 Other
650 _ 7 |a anxiety
|2 Other
650 _ 7 |a depression
|2 Other
650 _ 7 |a distress
|2 Other
650 _ 7 |a fear of progression
|2 Other
650 _ 7 |a non-motor symptoms
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Parkinson Disease: psychology
|2 MeSH
650 _ 2 |a Parkinson Disease: physiopathology
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Disease Progression
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Fear: psychology
|2 MeSH
650 _ 2 |a Age Factors
|2 MeSH
650 _ 2 |a Employment: statistics & numerical data
|2 MeSH
650 _ 2 |a Employment: psychology
|2 MeSH
650 _ 2 |a Anxiety: psychology
|2 MeSH
650 _ 2 |a Anxiety: epidemiology
|2 MeSH
650 _ 2 |a Quality of Life: psychology
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Depression: psychology
|2 MeSH
650 _ 2 |a Depression: epidemiology
|2 MeSH
650 _ 2 |a Surveys and Questionnaires
|2 MeSH
700 1 _ |a Tekampe, Esther
|b 1
700 1 _ |a Falkenburger, Björn
|0 P:(DE-2719)2814178
|b 2
700 1 _ |a Schnalke, Nils
|0 P:(DE-2719)9003291
|b 3
|e Last author
773 _ _ |a 10.1177/1877718X251365243
|g Vol. 16, no. 1, p. 170 - 176
|0 PERI:(DE-600)2599550-9
|n 1
|p 170 - 176
|t Journal of Parkinson's Disease
|v 16
|y 2026
|x 1877-7171
856 4 _ |u https://pub.dzne.de/record/285034/files/DZNE-2026-00159.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/285034/files/DZNE-2026-00159.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2814178
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9003291
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J PARKINSON DIS : 2022
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-10-23T11:51:45Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-10-23T11:51:45Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review, Double anonymous peer review
|d 2024-10-23T11:51:45Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-27
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-27
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-27
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J PARKINSON DIS : 2022
|d 2024-12-27
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-27
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-27
920 1 _ |0 I:(DE-2719)1710012
|k AG Falkenburger
|l Translational Parkinson Research
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1710012
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21